Table 3

Propensity score analysis results 1: Survival impact across quintiles based on the propensity to receive chemotherapy among patients with metastatic non-small cell lung cancer, who survived at least 3 months after their cancer diagnosis (n = 7,879)

Analysis

Variables

HR

(95%CI)

P-value


Stratified analysis

Lowest quintile of PS*

No chemotherapy

1.00

-

-

Chemotherapy

0.82

(0.73, 0.93)

< 0.01

Second quintile of PS

No chemotherapy

1.00

-

-

Chemotherapy

0.77

(0.69, 0.85)

< 0.001

Third quintile of PS

No chemotherapy

1.00

-

-

Chemotherapy

0.81

(0.74, 0.90)

< 0.001

Fourth quintile of PS

No chemotherapy

1.00

-

-

Chemotherapy

0.85

(0.77, 0.93)

< 0.01

Highest quintile of PS

No chemotherapy

1.00

-

-

Chemotherapy

0.73

(0.66, 0.81)

< 0.001

Multiple Cox regression adjustment using the PS

No chemotherapy

1.00

-

-

Chemotherapy

0.76

(0.71, 0.82)

< 0.001


Abbreviation: HR, hazard ratio; CI, confidence interval; PS, propensity score.

* Patients are least likely to receive "chemotherapy."

† Patients are most likely to receive "chemotherapy."

Saito et al. BMC Palliative Care 2011 10:14   doi:10.1186/1472-684X-10-14

Open Data